Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Psychedelic Education is a key component of the developing psychedelic industry. While people scramble to address various infrastructure problems in the industry, education is moving to the front of the line. Without qualified staff to carry out psychedelic treatment, all the new clinics and psychedelic legislation mean nothing. With this dire need for supply, comes…
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced positive results from its pre-clinical trial led by Professor Joseph Tam from The Hebrew University of Jerusalem, earlier this week. The treatment used in…
Cybin Inc. announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (?MDD?). Summary of CYB003 Phase 2 topline efficacy data: Rapid and large improvements in symptoms of depression observed after single doses of CYB003?: An average of 13.75 points…
Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia Scientific”, or the “Company”), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended September 30, 2023. Complete…
Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast)….
The “CNS Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global CNS Therapeutics Market to Reach $199 Billion by 2030 The global market for CNS Therapeutics estimated at US$114.9 Billion in the year 2022, is projected to reach a revised size of US$199 Billion by 2030, growing at a CAGR of 7.1% over the…
Q4 Fiscal 2023 Highlights Fiscal 2023 Highlights All financial results are reported in Canadian dollars unless otherwise stated. Numinus Wellness Inc. (“Numinus” or the “Company“) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and fiscal year ended August 31, 2023 (“Q4…
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.